Home

And The Answer Is…

Daniel Carlson -
0
For those who remember Carnac The Magnificent, the answer is "management is highly confident". Back in the dark ages of life before the internet, Johnny...
Read more

Anixa Biosciences and Cleveland Clinic Present Positive New Data from Phase 1 Study of...

Daniel Carlson -
0
TW's Take: excellent data from this novel vaccine program is setting the stage for Anixa to possibly change the whole landscape of cancer vaccine...
Read more

My Rally Cap is On!

Daniel Carlson -
12
The turkey hangover can last several hours or even up to a few days. You have overindulged and need to digest for a while...
Read more

Trading Thoughts…Premium Subscriber Update

Daniel Carlson -
3
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

Movano Health Announces Over $1M Black Friday Holiday Launch Results for the Evie Ring...

Daniel Carlson -
0
TW's Take: good to see this finally coming to market. I await glucose monitoring before I get too excited, however. PLEASANTON, Calif., Nov. 29, 2023 /PRNewswire/ -- Movano...
Read more

INmune Bio Inc. Demonstrates that INB03 Enhances the Uptake of Trastuzumab Deruxtecan in HER2+...

Daniel Carlson -
0
TW's Take: more exciting data that should perk interest in potential partnering of INB03. Pre-clinical but clinically relevant and potentially very meaningful for patients. ...
Read more

INmune Bio Receives EMA’s Authorization in France and Spain for Phase II Clinical Trial...

Daniel Carlson -
0
TW's Take: INMB is accelerating progress towards full enrollment. Results will be coming in late 2024, which is the key catalyst investors have been...
Read more

Anixa Biosciences Announces European Patent on Ovarian Cancer Vaccine Technology

Daniel Carlson -
0
TW's Take: while early stage, this is based on the same technology as their breast cancer vaccine which is showing great results in phase...
Read more

The Outlook For December

Daniel Carlson -
9
I hope everyone had a great Thanksgiving. Here in Charlottesville, we celebrated with family and friends. The weather was great, the turkey awesome and...
Read more

IN8bio’s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma

Daniel Carlson -
6
TW's Take: Solid progress with more data expected in December. IN8bio continues to execute but the balance sheet remains an issue and partnering has...
Read more

Turkey Day is Coming…Micro-Caps Have Been Turkeys For A While

Daniel Carlson -
4
As we head into the home stretch for 2023, the markets are back in rally mode. Performing best is the S&P 500 and Nasdaq...
Read more

Movano Health Announces Closing of $4.1 Million Public Offering Including Full Exercise of Over-Allotment...

Daniel Carlson -
0
TW's Take: much needed capital but this company remains very capital constrained. PLEASANTON, Calif., Nov. 17, 2023 /PRNewswire/ -- Movano Health (Nasdaq: MOVE) ("Movano Health" or...
Read more

enVVeno Medical Presents Positive Preliminary Device Related Material Adverse Event (MAE) Data from the...

Daniel Carlson -
0
TW's Take: very positive results sets the stage for approval if the efficacy data comes through as expected. We'll see that data in the...
Read more

The Year End Game Plan (part 2)…Premium Subscriber Update

Daniel Carlson -
3
~ This article is available for premium subscribers only. Please do not share the information here with non-premium subscribers or with company managements. Thank...
Read more

INmune Bio Inc. Announces Expansion of Phase II Clinical Trial for Alzheimer’s Disease in...

Daniel Carlson -
2
TW's Take: more jurisdictions approving the AD trial not only bodes well for enrollment but sets the company up for a well received phase...
Read more

Atomera Achieves Revenue Milestone Under First Commercial License Agreement

Daniel Carlson -
0
TW's Take: with the installation of MST in a customer's facility, ATOM has crossed a significant hurdle towards achieving their goals. While we are...
Read more

It’s Not A Sprint (It’s a Marathon)

Daniel Carlson -
7
This weekend is the Richmond Marathon. Billed as the "friendliest marathon", our daughter is going to be running in her first ever bid to...
Read more

TFF Pharmaceuticals Announces Publication of Data Demonstrating Feasibility of Intranasal Delivery of Monoclonal Antibodies...

Daniel Carlson -
0
TW's Take: the promise of TFF's technology continues to be advanced. Research shows the Company’s Thin Film Freezing can reformulate broad range of monoclonal...
Read more

IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with...

Daniel Carlson -
0
TW's Take: INAB's programs are showing great early-stage efficacy. Getting a late-breaking poster slot is proof that more, high-quality data is coming from IN8bio. ...
Read more

IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial in Newly Diagnosed...

Daniel Carlson -
0
TW's Take: data on Nov. 17th will likely be compelling. INAB continues to keep patients alive and progression free far longer than expected. Data...
Read more

Receive Our Weekly Newsletter

Every Sunday we recap the market and consolidate the news from our universe. It’s free to subscribe. Just click on the link below.

Newsletter Signup

Premium Membership

For those interested in doing a deeper dive into our coverage universe, we offer premium membership. Benefits of being a premium member include the following:

First Look: new names added to the portfolio, or stocks being removed, are shared with premium subscribers before anyone else.

Trade Alerts: when actionable events occur, we highlight the opportunities in an email to our premium subscribers

TW Private Chat Room: premium members have access to our exclusive chat room where more research and ideas are freely shared amongst the whole community.

SIGN ME UP

© TW Research Group LLC
DFC Advisory Services LLC (dba TW Research Group) is an investment adviser. We are also compensated for publishing information on certain companies. Information presented is for educational purposes only and does not intend to make an offer or solicitation for the sale or purchase of any specific securities, investments, or investment strategies. Investments involve risk and unless otherwise stated, are not guaranteed. Be sure to first consult with a qualified financial adviser and/or tax professional before implementing any strategy discussed herein. Past performance is not indicative of future performance.